8-KLeadership ChangesOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Executive Changes (Apr 4, 2018)

Filed April 4, 2018For Securities:ONCBEIGF

Summary

Beigene, Ltd. (ONC) filed an 8-K on April 4, 2018, primarily to announce two significant board-level changes. First, the company appointed Jing-Shyh (Sam) Su to its Board of Directors. Mr. Su brings extensive experience, including a significant tenure at Yum! Brands where he led their China division through substantial growth, and current roles with Hillhouse Capital and other boards. His appointment is expected to bolster the company's strategic planning and international business development, particularly in China. Second, the filing addresses a Nasdaq listing compliance issue. Effective April 1, 2018, the Board appointed existing director Timothy Chen to the Audit Committee. This move rectifies a prior non-compliance with Nasdaq's minimum audit committee member requirement and ensures the company remains in good standing with the exchange. Both appointments are effective as of April 1, 2018, and are detailed with compensation information for Mr. Su.

Key Highlights

  • 1Appointment of Jing-Shyh (Sam) Su to the Board of Directors as a Class I director.
  • 2Mr. Su's extensive background in China market development and executive leadership at Yum! Brands is highlighted.
  • 3Mr. Su's current affiliations include Hillhouse Capital and directorships at Li Ning Company Limited and Peet's Coffee China.
  • 4Mr. Su will receive compensation consistent with other independent directors, including a stock option grant, annual cash compensation, and annual equity grants.
  • 5Timothy Chen, an existing independent director, was appointed to the Audit Committee.
  • 6The appointment of Mr. Chen to the Audit Committee resolves a prior compliance issue with Nasdaq listing rules regarding the minimum number of audit committee members.
  • 7The company is now in compliance with Nasdaq's audit committee composition requirements.

Frequently Asked Questions